Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China
|
MSCI China Small-Cap
|
Hang Seng Index
|
Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

Share buyback

Founded in 2001 and listed in Hong Kong in 2010, Sihuan originally specialized in the production of cardiovascular and oncology generic drugs, and is one of the largest cardiovascular prescription drug suppliers in China.

FAST NEWS: Sihuan Pharma stock skyrockets on latest share buyback program

The Latest: Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK) on Sunday announced a new program to purchase up to HK$500 million ($64 million) worth of its shares on the open market over the next…
October 7, 2024
0460.HK
Fosun Pharma is a diversified drug company whose portfolio includes pharmaceutical, medical equipment and healthcare services.

FAST NEWS: Fosun Pharma hits pause button on share buyback program

The Latest: Shanghai Fosun Pharmaceutical (Group) Co. Ltd. (2196.HK; 600196.SH) announced Monday it hasn't yet implemented a share buyback since announcing a plan on March 27 to buy back its A shares…
May 7, 2024
2196.HK
600196.SHG
Drug developer Shanghai Junshi Biosciences said on Sunday its board has approved a plan to buy back some of its A-shares.

FAST NEWS: Junshi Biosciences announces A-Share buyback

The latest: Drug developer Shanghai Junshi Biosciences Co. Ltd. (1877.HK; 688180.SH) said on Sunday its board has approved a plan to buy back some of its A-shares for up to 58 yuan per…
September 11, 2023
1877.HK
688180.SHG

FAST NEWS: CanSino Spends $21 Million on Share Buyback

The latest: CanSino Biologics Inc. (6185.HK; 688185.SH) said Friday it bought back about 670,000 of its Shanghai-listed A-shares for 147 million yuan ($20.8 million) as of Nov. 30, accounting for…
December 2, 2022

FAST NEWS: WuXi Biologics Announces $300 Million Share Buyback

The latest: Contract drugs services provider WuXi Biologics (Cayman) Inc. (2269.HK) announced on Monday its board of directors has approved a plan to buy back up to $300 million of the…
September 26, 2022

Recent Articles

Founded in 2001 and listed in Hong Kong in 2010, Sihuan originally specialized in the production of cardiovascular and oncology generic drugs, and is one of the largest cardiovascular prescription drug suppliers in China.
October 7, 2024

FAST NEWS: Sihuan Pharma stock skyrockets on latest share buyback program

0460.HK
May 7, 2024

FAST NEWS: Fosun Pharma hits pause button on share buyback program

2196.HK
600196.SHG
September 11, 2023

FAST NEWS: Junshi Biosciences announces A-Share buyback

1877.HK
688180.SHG
December 2, 2022

FAST NEWS: CanSino Spends $21 Million on Share Buyback

September 26, 2022

FAST NEWS: WuXi Biologics Announces $300 Million Share Buyback

RELATED ARTICLES

No related posts.

Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2025 Bamboo Works. All rights reserved.